Cellectis
- Country
- Ownership
- -
- Employees
- 221
- Market Cap
- -
- Introduction
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 80
- Registration Number
- NCT05607420
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: UCART22Biological: CLLS52
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 40
- Registration Number
- NCT04150497
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio, Texas, United States
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Biological: UCARTCS1A
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 11
- Registration Number
- NCT04142619
- Locations
- 🇺🇸
Winship Cancer Institute Emory University, Atlanta, Georgia, United States
🇺🇸Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸UCSF Medical Center- Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukaemia
- Interventions
- Biological: UCART123
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Cellectis S.A.
- Registration Number
- NCT04106076
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Interventions
- Biological: UCART123
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 1
- Registration Number
- NCT03203369
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- Biological: UCART123v1.2
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 65
- Registration Number
- NCT03190278
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States